Guardant Health recently celebrated a milestone at the Nasdaq MarketSite in Times Square as their product, Shield, became the first FDA-approved blood test for primary colorectal cancer screening. This innovative test detects cancer signals in the bloodstream from DNA shed by tumors, offering a less invasive screening option. Co-CEOs and Co-Founders, Helmy Eltoukhy and AmirAli Talasaz, marked the occasion by ringing the Opening Bell at Nasdaq.
Keep Reading
Add A Comment